| Machine learning in drug discovery and development part 1: a primer A Talevi, JF Morales, G Hather, JT Podichetty, S Kim, PC Bloomingdale, ... CPT: pharmacometrics & systems pharmacology 9 (3), 129-142, 2020 | 54 | 2020 |
| Validation of rapid and simple LC–MS/MS method for determination of voriconazole in rat plasma BV Araujo, DJ Conrado, EC Palma, T Dalla Costa Journal of Pharmaceutical and Biomedical analysis 44 (4), 985-990, 2007 | 53 | 2007 |
| Pharmacokinetic evaluation of LASSBio‐579: an N‐phenylpiperazine antipsychotic prototype DJ Conrado, H Verli, G Neves, CAM Fraga, EJ Barreiro, SMK Rates, ... Journal of Pharmacy and Pharmacology 60 (6), 699-707, 2008 | 47 | 2008 |
| The effect of critical illness on drug distribution D Gonzalez, D J Conrado, U Theuretzbacher, H Derendorf Current pharmaceutical biotechnology 12 (12), 2030-2036, 2011 | 43 | 2011 |
| Consistency of drug–drug and gene–drug interaction information in US FDA-approved drug labels DJ Conrado, HL Rogers, I Zineh, MA Pacanowski Pharmacogenomics 14 (2), 215-223, 2013 | 41 | 2013 |
| Open innovation: Towards sharing of data, models and workflows DJ Conrado, MO Karlsson, K Romero, C Sarr, JJ Wilkins European Journal of Pharmaceutical Sciences 109, S65-S71, 2017 | 37 | 2017 |
| An updated Alzheimer’s disease progression model: incorporating non-linearity, beta regression, and a third-level random effect in NONMEM DJ Conrado, WS Denney, D Chen, K Ito Journal of pharmacokinetics and pharmacodynamics 41, 581-598, 2014 | 37 | 2014 |
| Dopamine transporter neuroimaging as an enrichment biomarker in early Parkinson's disease clinical trials: a disease progression modeling analysis DJ Conrado, T Nicholas, K Tsai, S Macha, V Sinha, J Stone, B Corrigan, ... Clinical and Translational Science 11 (1), 63-70, 2018 | 35 | 2018 |
| The qualification of an enrichment biomarker for clinical trials targeting early stages of Parkinson’s disease D Stephenson, D Hill, JM Cedarbaum, M Tome, S Vamvakas, K Romero, ... Journal of Parkinson's disease 9 (3), 553-563, 2019 | 32 | 2019 |
| Model‐informed development and registration of a once‐daily regimen of extended‐release tofacitinib M Lamba, MM Hutmacher, DE Furst, A Dikranian, ME Dowty, D Conrado, ... Clinical Pharmacology & Therapeutics 101 (6), 745-753, 2017 | 29 | 2017 |
| Predicting the probability of successful efficacy of a dissociated agonist of the glucocorticoid receptor from dose–response analysis DJ Conrado, S Krishnaswami, S Shoji, S Kolluri, J Hey-Hadavi, ... Journal of pharmacokinetics and pharmacodynamics 43, 325-341, 2016 | 28 | 2016 |
| Open data revolution in clinical research: opportunities and challenges MH Shahin, S Bhattacharya, D Silva, S Kim, J Burton, J Podichetty, ... Clinical and Translational Science 13 (4), 665-674, 2020 | 25 | 2020 |
| Genome‐wide association approach identified novel genetic predictors of heart rate response to β‐blockers MH Shahin, DJ Conrado, D Gonzalez, Y Gong, MT Lobmeyer, ... Journal of the American Heart Association 7 (5), e006463, 2018 | 19 | 2018 |
| A Markov Chain Model to Evaluate the Effect of CYP3A5 and ABCB1 Polymorphisms on Adverse Events Associated with Tacrolimus in Pediatric Renal … SKB Sy, J Heuberger, S Shilbayeh, DJ Conrado, H Derendorf The AAPS journal 15, 1189-1199, 2013 | 19 | 2013 |
| Gastroresistant microparticles containing sodium alendronate prevent the bone loss in ovariectomized rats L Cruz, E Assumpção, SF Andrade, DJ Conrado, IC Kulkamp, ... European journal of pharmaceutical sciences 40 (5), 441-447, 2010 | 19 | 2010 |
| Microencapsulation of sodium alendronate reduces drug mucosal damage in rats L Cruz, E Assumpção, SF Andrade, DJ Conrado, SS Guterres, ... Drug delivery 17 (4), 231-237, 2010 | 19 | 2010 |
| Serotonergic neurotransmission mediates hypothermia induced by the N-phenylpiperazine antipsychotic prototypes LASSBio-579 and LASSBio-581 G Neves, M Kliemann, AH Betti, DJ Conrado, L Tasso, CAM Fraga, ... Pharmacology Biochemistry and Behavior 89 (1), 23-30, 2008 | 19 | 2008 |
| Development of a model‐based clinical trial simulation platform to optimize the design of clinical trials for Duchenne muscular dystrophy K Lingineni, V Aggarwal, JF Morales, DJ Conrado, D Corey, C Vong, ... CPT: Pharmacometrics & Systems Pharmacology 11 (3), 318-332, 2022 | 17 | 2022 |
| Towards regulatory endorsement of drug development tools to promote the application of model-informed drug development in Duchenne muscular dystrophy DJ Conrado, J Larkindale, A Berg, M Hill, J Burton, KR Abrams, ... Journal of pharmacokinetics and pharmacodynamics 46, 441-455, 2019 | 17 | 2019 |
| Molecular neuroimaging of the dopamine transporter as a patient enrichment biomarker for clinical trials for early Parkinson's disease K Romero, D Conrado, J Burton, T Nicholas, V Sinha, S Macha, ... Clinical and Translational Science 12 (3), 240-246, 2019 | 16 | 2019 |
